Comparative Pharmacology
Head-to-head clinical analysis: CARDIOGRAFIN versus CHOLETEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOGRAFIN versus CHOLETEC.
CARDIOGRAFIN vs CHOLETEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardiografin is an ionic, high-osmolar iodinated contrast agent used for radiographic imaging. It enhances contrast by attenuating X-rays, primarily due to the iodine content. It distributes in the extracellular space and is excreted unchanged by glomerular filtration.
Choletec is a technetium-99m labeled iminodiacetic acid derivative used for hepatobiliary scintigraphy. It is taken up by hepatocytes via organic anion transporting polypeptides and excreted into bile canaliculi via multidrug resistance-associated protein 2, allowing visualization of the biliary system.
Adult: 50-100 mL of CARDIOGRAFIN (diatrizoate meglumine and diatrizoate sodium) 76% intravenously as a bolus or rapid infusion. For cardiac ventriculography, 40-50 mL into the left ventricle. For coronary arteriography, 5-10 mL selective injection per artery.
1 gram intravenously every 8 hours; maximum 3 g/day.
None Documented
None Documented
Terminal elimination half-life ~2 hours (normal renal function). May be prolonged to >20 hours in severe renal impairment (e.g., CrCl <30 mL/min).
Terminal elimination half-life is approximately 16–24 hours; clinically, once-daily dosing achieves steady-state after 5–7 days, allowing for pharmacological effects on bile acid composition.
Primarily renal (glomerular filtration) with >90% of dose excreted unchanged in urine within 24 hours; less than 1% biliary/fecal; negligible metabolism.
Primarily biliary (approx. 50–70% as unchanged drug and metabolites) with fecal elimination; renal excretion is minimal (<5% unchanged).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent